Auven Therapeutics Announces Completion of Enrollment in Confirmatory Phase 3 Clinical Trial of Seciera (OTX-101) for the Treatment of Dry Eye Disease

-Pivotal study to confirm significant improvements in tear production and ocular surface inflammation in patients with dry eye disease, with top-line results anticipated by year-end.
-Seciera poised for significant commercial opportunity as a highly competitive entrant in dry eye disease market.

Read the full press release